RHJA
BHVN

Rice Hall James & Associates’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Rice Hall James & Associates’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-82,110
Closed -$12.4M – 276
2022
Q3 		$12.4M Sell
82,110
-180,920
-69% -$26.8M 0.72% 43
2022
Q2 		$38.3M Sell
263,030
-13,976
-5% -$1.79M 1.85% 13
2022
Q1 		$32.8M Sell
277,006
-4,945
-2% -$617K 1.31% 19
2021
Q4 		$38.9M Sell
281,951
-1,799
-0.6% -$229K 1.38% 19
2021
Q3 		$39.4M Sell
283,750
-7,111
-2% -$888K 1.46% 19
2021
Q2 		$28.2M Buy
290,861
+26,303
+10% +$2.13M 1% 31
2021
Q1 		$18.1M Buy
+264,558
New +$21.4M 0.59% 51

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return

Rice Hall James & Associates's BHVN Position: Q4 2022 in Review

Rice Hall James & Associates sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 82,110 shares — an estimated $12.4M sold.

Rice Hall James & Associates first reported a position in BHVN in Q1 2021 and held it in 7 quarters. The position peaked at $39.4M in Q3 2021. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • Rice Hall James & Associates reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • Rice Hall James & Associates sold 82,110 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $12.4M.
  • Rice Hall James & Associates first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q1 2021 and held it in 7 quarters.
  • Rice Hall James & Associates's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $39.4M in Q3 2021.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on Rice Hall James & Associates's 13F filing for Q4 2022, filed 27 Jan 2023.